AI assistant
CRISPR Therapeutics AG — Director's Dealing 2025
Mar 18, 2025
30936_dirs_2025-03-18_af230d2a-47a7-4603-b8c8-6fcead43211a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2025-03-14
Reporting Person: Patel Naimish (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-14 | Stock Option (Right to Buy) | $42.12 | A | 46667 | Acquired | 2035-03-14 | Common Shares (46667) | Direct |
| 2025-03-14 | Restricted Stock Units | $ | A | 32500 | Acquired | Common Shares (32500) | Direct |
Footnotes
F1: This option was granted on March 14, 2025 with respect to 46,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.